Invitrogen™ Teprotumumab Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA541915	100 μg

Catalog No. PIMA541915 Supplier Invitrogen™ Supplier No. MA541915

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. 8 Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received 'breakthrough therapy' designation from the FDA in 20163 and was approved by the FDA in January 2020 for the treatment of TED. 7 Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries - teprotumumab is the first pharmaceutical ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.

Specifications

• Antigen: Teprotumumab
• Applications: ELISA, SDS-Page
• Classification: Recombinant Monoclonal
• Concentration: 1.74 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: RO4858696-000
• Host Species: Human
• Immunogen: Human IGF1R/CD221.
• Purification Method: Protein A/G
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG1
• Target Molecule: Chemical

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov